Opus Genetics Stock Forecast
NASDAQ: IRDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
After hours: 4.49 +0.67%
IRD analyst consensus
Consensus (18 analysts)
strong_buy
Avg. price target
$13.41+200.67%
- Strong buy 3
- Buy 15
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 18 Wall Street analysts covering Opus Genetics (2026-10-08), 18 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $13.41, with a high estimate of $20.00 and a low estimate of $8.00. The average target implies upside of 200.7% from the current price of $4.46.
The spread between the highest and lowest targets is 150.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for IRD.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 3 | 17% |
| Buy | 15 | 83% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $8.00 | +79.37% |
| Average target | $13.41 | +200.67% |
| High target | $20.00 | +348.43% |